PATHFINDER 2 Study

This is a prospective, multi-center interventional study of the Galleri multi-cancer early detection test with return of test results for participants enrolled through healthcare systems in North America.

View Study

REFLECTION Study

An observational study of patients administered the Galleri test.

View Study

NHS-Galleri Trial

A validation study of Galleri’s clinical and economic performance in the United Kingdom’s National Health System

View Study

SUMMIT Study

A prospective, observational, longitudinal, cohort study in London, United Kingdom. The study is designed to enroll approximately 13,000 men and women who do not have a cancer diagnosis at the time of enrollment.

View Study

STRIVE Study

A prospective, observational, longitudinal, cohort study that enrolled approximately 100,000 women to help validate Galleri in an asymptomatic and intended use population.

View Study

The Circulating Cell-free Genome Atlas (CCGA) Study

An observational, longitudinal study designed to characterize the landscape of genomic cancer signals in the blood of people with and without cancer. The study is being used to discover, train, and validate GRAIL’s products.

View Study

PATHFINDER Study

A prospective, interventional, multi-center study evaluating an earlier version of Galleri in clinical practice. PATHFINDER is our first study that returns results to physicians and participants to evaluate how these test results affect diagnostic and care pathways in a screening population.

View Study